blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3555308

EP3555308 - EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.10.2024
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  10.11.2023
FormerGrant of patent is intended
Status updated on  04.07.2023
FormerExamination is in progress
Status updated on  16.06.2023
FormerGrant of patent is intended
Status updated on  23.02.2023
FormerExamination is in progress
Status updated on  16.12.2022
FormerGrant of patent is intended
Status updated on  08.08.2022
FormerExamination is in progress
Status updated on  10.06.2020
FormerRequest for examination was made
Status updated on  20.09.2019
FormerThe international publication has been made
Status updated on  23.06.2018
Formerunknown
Status updated on  24.01.2018
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Eurofins Genomics Europe Sequencing GmbH
European Genome and
Diagnostics Centre
Jakob-Stadler-Platz 7
78467 Konstanz / DE
For all designated states
Genedata AG
Margarethenstrasse 38
4053 Basel / CH
For all designated states
UCL Business Ltd
University College London
Gower Street
London WC1E 6BT / GB
[2022/13]
Former [2020/11]For all designated states
Eurofins Genomics Europe Sequencing GmbH
European Genome and
Diagnostics Centre
Jakob-Stadler-Platz 7
78467 Konstanz / DE
For all designated states
Genedata AG
Margarethenstrasse 38
4053 Basel / CH
For all designated states
UCL Business Ltd
The Network Building
97 Tottenham Court Road
London W1T 4TP / GB
Former [2019/43]For all designated states
Eurofins Genomics Europe Sequencing GmbH
European Genome and
Diagnostics Centre
Jakob-Stadler-Platz 7
78467 Konstanz / DE
For all designated states
Genedata AG
Margarethenstrasse 38
4053 Basel / CH
For all designated states
UCL Business PLC
The Network Building
97 Tottenham Court Road
London, W1T 4TP / GB
Inventor(s)01 / WIDSCHWENDTER, Martin
Weidenweg 5
6413 Wildermieming / AT
02 / JONES, Allison
454E Upper Richmond Road
Barnes
London SW15 5RQ / GB
03 / EVANS, Iona
Flat 44 Avenue Close
Avenue Road
London NW8 6DA / GB
04 / LEMPIÄINEN, Harri
Schafmattweg 46
4102 Binningen / CH
05 / EICHNER, Johannes
Wallbrunnstrasse 880
79539 Lörrach / DE
06 / RUJAN, Tamas
Hafenrainstrasse 40
4104 Oberwil / CH
07 / WITTENBERGER, Timo
Am alten Sägewerk 12
78467 Konstanz / DE
08 / PAPROTKA, Tobias
Sorbenstraße 9
04159 Leipzig / DE
09 / LINDNER Benjamin
Geschwister-Herschel-Str. 3
88471 Laupheim / DE
 [2023/30]
Former [2023/22]01 / WIDSCHWENDTER, Martin
Weidenweg 5
6413 Wildermieming / AT
02 / JONES, Allison
454E Upper Richmond Road
Barnes
London SW15 5RQ / GB
03 / EVANS, Iona
Flat 44 Avenue Close
Avenue Road
London NW8 6DA / GB
04 / LEMPPIÄINEN, Harri
Schafmattweg 46
4102 Binningen / CH
05 / EICHNER, Johannes
Wallbrunnstrasse 880
79539 Lörrach / DE
06 / RUJAN, Tamas
Hafenrainstrasse 40
4104 Oberwil / CH
07 / WITTENBERGER, Timo
Am alten Sägewerk 12
78467 Konstanz / DE
08 / PAPROTKA, Tobias
Sorbenstraße 9
04159 Leipzig / DE
09 / LINDNER Benjamin
Geschwister-Herschel-Str. 3
88471 Laupheim / DE
Former [2019/43]01 / WIDSCHWENDTER, Martin
Weidenweg 5
6134 Wildermieming / AT
02 / JONES, Allison
454E Upper Richmond Road
Barnes
London SW15 5RQ / GB
03 / EVANS, Iona
2 Wavertree Court
Streatham
London Hill SW2 4TL / GB
04 / LEMPPIÄINEN, Harri
Schafmattweg 46
4102 Binningen / CH
05 / EICHNER, Johannes
Wallbrunnstrasse 74
79539 Lörrach / DE
06 / RUJAN, Tamas
Schützenstrasse 13
4103 Bottmingen / CH
07 / WITTENBERGER, Timo
Am alten Sägewerk 12
78467 Konstanz / DE
08 / PAPROTKA, Tobias
Berchenstrasse 66
78467 Konstanz / DE
09 / WAHL, Benjamin
Gartenstrasse 5
88471 Laupheim / DE
Representative(s)Oetke, Cornelia
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstraße 5-7
80331 München / DE
[2019/43]
Application number, filing date17829175.315.12.2017
[2019/43]
WO2017EP83170
Priority number, dateEP2016020482216.12.2016         Original published format: EP 16204822
[2019/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018109217
Date:21.06.2018
Language:EN
[2018/25]
Type: A1 Application with search report 
No.:EP3555308
Date:23.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.06.2018 takes the place of the publication of the European patent application.
[2019/43]
Type: B1 Patent specification 
No.:EP3555308
Date:13.12.2023
Language:EN
[2023/50]
Search report(s)International search report - published on:EP21.06.2018
ClassificationIPC:C12Q1/68
[2019/43]
CPC:
C12Q1/6886 (EP,US); G16B20/00 (US); G16B40/10 (US);
G16H20/00 (US); G16H50/20 (US); C12Q2600/106 (US);
C12Q2600/112 (US); C12Q2600/118 (EP,US); C12Q2600/154 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/43]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:EPIGENETISCHE MARKER UND ENTSPRECHENDE VERFAHREN UND MITTEL ZUM NACHWEIS UND MANAGEMENT VON EIERSTOCKKREBS[2021/51]
English:EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERS[2019/43]
French:MARQUEURS ÉPIGÉNÉTIQUES ET PROCÉDÉS ASSOCIÉS ET MOYENS DE DÉTECTION ET DE GESTION DU CANCER DES OVAIRES[2021/51]
Former [2019/43]EPIGENETISCHE MARKER UND ENTSPRECHENDE VERFAHREN SOWIE MITTEL FÜR DEN NACHWEIS UND DAS MANAGEMENT BESTIMMTER KREBSARTEN
Former [2019/43]MARQUEURS ÉPIGÉNÉTIQUES ET PROCÉDÉS ET MOYENS ASSOCIÉS POUR LA DÉTECTION ET LA PRISE EN CHARGE DE CERTAINS CANCERS
Entry into regional phase13.06.2019National basic fee paid 
13.06.2019Designation fee(s) paid 
13.06.2019Examination fee paid 
Examination procedure13.06.2019Examination requested  [2019/43]
13.06.2019Date on which the examining division has become responsible
03.02.2020Amendment by applicant (claims and/or description)
16.06.2020Despatch of a communication from the examining division (Time limit: M06)
22.12.2020Reply to a communication from the examining division
22.01.2021Despatch of a communication from the examining division (Time limit: M06)
24.08.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
02.11.2021Reply to a communication from the examining division
14.12.2021Despatch of a communication from the examining division (Time limit: M06)
21.06.2022Reply to a communication from the examining division
09.08.2022Communication of intention to grant the patent
16.12.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.02.2023Communication of intention to grant the patent
16.06.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.07.2023Communication of intention to grant the patent
03.11.2023Fee for grant paid
03.11.2023Fee for publishing/printing paid
03.11.2023Receipt of the translation of the claim(s)
Opposition(s)16.09.2024No opposition filed within time limit [2024/47]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
02.11.2021Request for further processing filed
02.11.2021Full payment received (date of receipt of payment)
Request granted
11.11.2021Decision despatched
Fees paidRenewal fee
20.03.2020Renewal fee patent year 03
21.12.2020Renewal fee patent year 04
16.12.2021Renewal fee patent year 05
15.12.2022Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.12.201903   M06   Fee paid on   20.03.2020
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY15.12.2017
HU15.12.2017
CZ13.12.2023
ES13.12.2023
HR13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
TR13.12.2023
IE15.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
[2026/04]
Former [2025/39]CY15.12.2017
HU15.12.2017
CZ13.12.2023
ES13.12.2023
HR13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
IE15.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2025/36]CY15.12.2017
CZ13.12.2023
ES13.12.2023
HR13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
IE15.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/46]CZ13.12.2023
ES13.12.2023
HR13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
IE15.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/45]CZ13.12.2023
ES13.12.2023
HR13.12.2023
MC13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/36]CZ13.12.2023
ES13.12.2023
HR13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SK13.12.2023
SM13.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/35]CZ13.12.2023
ES13.12.2023
HR13.12.2023
RO13.12.2023
RS13.12.2023
SM13.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/33]ES13.12.2023
HR13.12.2023
RS13.12.2023
SM13.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/32]ES13.12.2023
HR13.12.2023
RS13.12.2023
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/24]ES13.12.2023
HR13.12.2023
RS13.12.2023
NO13.03.2024
GR14.03.2024
Former [2024/20]GR14.03.2024
Cited inInternational search[X] WO2016109712  (UNIV CASE WESTERN RESERVE et al.)
 [X] WO2009153667  (OCCURE GMBH et al.)
 [X] WO2013033627  (UNIV CALIFORNIA et al.)
 [XP] WO2017048932  (US HEALTH et al.)
 [I]   ZHANG QING ET AL: "A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 130, no. 1, 25 April 2013 (2013-04-25), pages 132 - 139, XP028569267, ISSN: 0090-8258, DOI: 10.1016/J.YGYNO.2013.04.048

DOI:   http://dx.doi.org/10.1016/j.ygyno.2013.04.048
 [I]   LIGGETT T E ET AL: "Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 120, no. 1, 1 January 2011 (2011-01-01), pages 113 - 120, XP027552592, ISSN: 0090-8258, [retrieved on 20101208]
 [I]   AMY E BONDURANT ET AL: "Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 123, no. 3, 29 August 2011 (2011-08-29), pages 581 - 587, XP028110052, ISSN: 0090-8258, [retrieved on 20110907], DOI: 10.1016/J.YGYNO.2011.08.029

DOI:   http://dx.doi.org/10.1016/j.ygyno.2011.08.029
 [I]   G. GIFFORD: "The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients", CLINICAL CANCER RESEARCH, vol. 10, no. 13, 1 July 2004 (2004-07-01), US, pages 4420 - 4426, XP055372612, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-03-0732

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-03-0732
 [X]   DATABASE Geneseq [online] 25 August 2016 (2016-08-25), "Human bisulfite-converted methylated genomic DNA plus-strand, SEQ: 7909.", XP002773556, retrieved from EBI accession no. GSN:BDC31189 Database accession no. BDC31189
 [X]   "Human bisulfite-converted genomic DNA plus-strand (control), SEQ: 5972", GENESEQ,, 25 August 2016 (2016-08-25), XP002773555
 [X]   "Human bisulfite-converted genomic DNA plus-strand (control), SEQ: 3801", GENESEQ,, 25 August 2016 (2016-08-25), XP002773554
 [X]   DATABASE Geneseq [online] 4 March 2010 (2010-03-04), "Human methylated bisulfite sense strand target genomic DNA, SEQ:498.", XP002773557, retrieved from EBI accession no. GSN:AXU31500 Database accession no. AXU31500
 [XP]   DATABASE Geneseq [online] 18 May 2017 (2017-05-18), "Human chromosome 19 genome fragment (58220404-58220705), SEQ ID NO 5.", XP002773558, retrieved from EBI accession no. GSN:BDS79696 Database accession no. BDS79696
by applicantWO0218631
 WO0218632
 WO2007019670
 EP1862555
 WO2009153667
 WO2012104642
 WO2012138609
 WO2012143481
 US2013041047
 WO2013009661
 US6200756
 EP0954608
 US6331393
 EP1185695
 USD50048
   ARAI ET AL., CARCINOGENESIS, vol. 33, 2012, pages 1487
   REINERT ET AL., PLOS ONE, vol. 10, 2012, pages e46297
   LEGENDRE ET AL., CLINICAL EPIGENOMICS, vol. 7, 2015, pages 100
   TESCHENDORFF, PLOS ONE, vol. 4, 2009, pages e8274
   SIEGEL ET AL., A CANCER JOURNAL FOR CLINICIANS, vol. 67, 2017, pages 7
   YEGNASUBRAMANIAN ET AL., NUC ACID RES, vol. 34, 2006, pages e19
   NATURE, vol. 467, pages 190
   MOORE ET AL., GYNECOLOGICAL ONCOLOGY, vol. 112, 2009, pages 49
   MALKASIAN, AM J OBSTET GYNECOL, vol. 159, 1988, pages 341
   UELAND ET AL., OBSTET GYNECOL, vol. 117, 2009, pages 1289
   WARE MILLER ET AL., OBSTET GYNECOL, vol. 117, 2011, pages 1298
   HENNESSY BT; COLEMAN RL; MARKMAN M., OVARIAN CANCER, vol. 374, no. 9698, 2009, pages 1371 - 1382
   BOWTELL DD; BOHM S; AHMED AA ET AL.: "Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer", NAT REV CANCER, vol. 15, no. 11, 2015, pages 668 - 679
   BAST RC, JR.; KLUG TL; ST JE ET AL.: "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer", N ENGL J MED, vol. 309, no. 15, 1983, pages 883 - 887, XP000610621
   BUYS SS; PARTRIDGE E; BLACK A ET AL.: "Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial", JAMA, vol. 305, no. 22, 2011, pages 2295 - 2303
   CRAMER DW; BAST RC, JR.; BERG CD ET AL.: "Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens", CANCER PREV RES (PHILA, vol. 4, no. 3, 2011, pages 365 - 374
   JACOBS IJ; MENON U; RYAN A ET AL.: "Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial", LANCET, vol. 387, no. 10022, 2016, pages 945 - 956, XP029453155, DOI: doi:10.1016/S0140-6736(15)01224-6

DOI:   http://dx.doi.org/10.1016/S0140-6736(15)01224-6
   MENON U; RYAN A; KALSI J ET AL.: "Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening", J CLIN ONCOL, vol. 33, no. 18, 2015, pages 2062 - 2071
   VALLIUS T; HYNNINEN J; AURANEN A ET AL.: "Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer", TUMOUR BIOL, vol. 35, no. 12, 2014, pages 12389 - 12395, XP035415622, DOI: doi:10.1007/s13277-014-2553-1

DOI:   http://dx.doi.org/10.1007/s13277-014-2553-1
   DAWSON SJ; TSUI DW; MURTAZA M ET AL.: "Analysis of circulating tumor DNA to monitor metastatic breast cancer", N ENGL J MED, vol. 368, no. 13, 2013, pages 1199 - 1209
   MURTAZA M; DAWSON SJ; TSUI DW ET AL.: "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA", NATURE, vol. 497, no. 7447, 2013, pages 108 - 112, XP055403638, DOI: doi:10.1038/nature12065

DOI:   http://dx.doi.org/10.1038/nature12065
   WANG Y; SPRINGER S; MULVEY CL ET AL.: "Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas", SCI TRANSL MED, vol. 7, no. 293, 2015, pages 293ra104, XP055341353, DOI: doi:10.1126/scitranslmed.aaa8507

DOI:   http://dx.doi.org/10.1126/scitranslmed.aaa8507
   SIRAVEGNA G; MUSSOLIN B; BUSCARINO M ET AL.: "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients", NAT MED, vol. 21, no. 7, 2015, pages 827
   BETTEGOWDA C; SAUSEN M; LEARY RJ ET AL.: "Detection of circulating tumor DNA in early- and late-stage human malignancies", SCI TRANSL MED, vol. 6, no. 224, 2014, pages 224ra24
   LANMAN RB; MORTIMER SA; ZILL OA ET AL.: "Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA", PLOS ONE, vol. 10, no. 10, 2015, pages e0140712, XP055403636, DOI: doi:10.1371/journal.pone.0140712

DOI:   http://dx.doi.org/10.1371/journal.pone.0140712
   SUN K; JIANG P; CHAN KC ET AL.: "Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments", PROC NATL ACAD SCI U S A, vol. 112, no. 40, 2015, pages E5503 - E5512, XP055373988, DOI: doi:10.1073/pnas.1508736112

DOI:   http://dx.doi.org/10.1073/pnas.1508736112
   PEPE MS; FENG Z; JANES H; BOSSUYT PM; POTTER JD: "Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design", J NATL CANCER INST, vol. 100, no. 20, 2008, pages 1432 - 1438, XP055167125, DOI: doi:10.1093/jnci/djn326

DOI:   http://dx.doi.org/10.1093/jnci/djn326
   BAYLIN SB; JONES PA.: "A decade of exploring the cancer epigenome - biological and translational implications", NAT REV CANCER, vol. 11, no. 10, 2011, pages 726 - 734, XP055045165, DOI: doi:10.1038/nrc3130

DOI:   http://dx.doi.org/10.1038/nrc3130
   FORSHEW T; MURTAZA M; PARKINSON C ET AL.: "Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA", SCI TRANSL MED, vol. 4, no. 136, 2012, pages 136ra68, XP055450222, DOI: doi:10.1126/scitranslmed.3003726

DOI:   http://dx.doi.org/10.1126/scitranslmed.3003726
   LEARY RJ; SAUSEN M; KINDE I ET AL.: "Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing", SCI TRANSL MED, vol. 4, no. 162, 2012, pages 162ra154
   WITTENBERGER T; SLEIGH S; REISEL D ET AL.: "DNA methylation markers for early detection of women's cancer: promise and challenges", EPIGENOMICS, vol. 6, no. 3, 2014, pages 311 - 327, XP055371973, DOI: doi:10.2217/epi.14.20

DOI:   http://dx.doi.org/10.2217/epi.14.20
   POTTER NT; HURBAN P; WHITE MN ET AL.: "Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma", CLIN CHEM, vol. 60, no. 9, 2014, pages 1183 - 1191, XP055359854, DOI: doi:10.1373/clinchem.2013.221044

DOI:   http://dx.doi.org/10.1373/clinchem.2013.221044
   NORTON ME; JACOBSSON B; SWAMY GK ET AL.: "Cell-free DNA analysis for noninvasive examination of trisomy", N ENGL J MED, vol. 372, no. 17, 2015, pages 1589 - 1597
   MENON U; GENTRY-MAHARAJ A; HALLETT R ET AL.: "Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS", LANCET ONCOL, vol. 10, no. 4, 2009, pages 327 - 340, XP026079736, DOI: doi:10.1016/S1470-2045(09)70026-9

DOI:   http://dx.doi.org/10.1016/S1470-2045(09)70026-9
   TESCHENDORFF AE; YANG Z; WONG A ET AL.: "Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer", JAMA ONCOL, vol. 1, no. 4, 2015, pages 476 - 485
   TESCHENDORFF AE; LEE SH; JONES A ET AL.: "HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer", GENOME MED, vol. 7, no. 1, 2015, pages 108, XP021230986, DOI: doi:10.1186/s13073-015-0233-4

DOI:   http://dx.doi.org/10.1186/s13073-015-0233-4
   GU H; SMITH ZD; BOCK C; BOYLE P; GNIRKE A; MEISSNER A: "Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling", NAT PROTOC, vol. 6, no. 4, 2011, pages 468 - 481, XP055151116, DOI: doi:10.1038/nprot.2010.190

DOI:   http://dx.doi.org/10.1038/nprot.2010.190
   LEE YK; JIN S; DUAN S ET AL.: "Improved reduced representation bisulfite sequencing for epigenomic profiling of clinical samples", BIOL PROCED ONLINE, vol. 16, no. 1, 2014, pages 1, XP021172647, DOI: doi:10.1186/1480-9222-16-1

DOI:   http://dx.doi.org/10.1186/1480-9222-16-1
   NEWCOMBE RG: "Two-sided confidence intervals for the single proportion: comparison of seven methods", STAT MED, vol. 17, no. 8, 1998, pages 857 - 872
   BARTLETT TE; JONES A; GOODE EL ET AL.: "Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers", PLOS ONE, vol. 10, no. 12, 2015, pages e0143178
   SANCHEZ-VEGA F; GOTEA V; PETRYKOWSKA HM ET AL.: "Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines", EPIGENETICS, vol. 8, no. 12, 2013, pages 1355 - 1372, XP055320214, DOI: doi:10.4161/epi.26701

DOI:   http://dx.doi.org/10.4161/epi.26701
   MARGOLIN G; PETRYKOWSKA HM; JAMEEL N; BELL DW; YOUNG AC; ELNITSKI L: "Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development", J MOL DIAGN, vol. 18, no. 2, 2016, pages 283 - 298, XP055320203, DOI: doi:10.1016/j.jmoldx.2015.11.004

DOI:   http://dx.doi.org/10.1016/j.jmoldx.2015.11.004
   GORMALLY E; CABOUX E; VINEIS P; HAINAUT P: "Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance", MUTAT RES, vol. 635, no. 2-3, 2007, pages 105 - 117, XP022085870, DOI: doi:10.1016/j.mrrev.2006.11.002

DOI:   http://dx.doi.org/10.1016/j.mrrev.2006.11.002
   JIANG P; LO YM: "The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics", TRENDS GENET, vol. 32, no. 6, 2016, pages 360 - 371, XP029538999, DOI: doi:10.1016/j.tig.2016.03.009

DOI:   http://dx.doi.org/10.1016/j.tig.2016.03.009
   HIRSCH M; DUFFY J; DAVIS CJ; NIEVES PM; KHAN KS: "Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis", BJOG, 2016
   KANG Q; HENRY NL; PAOLETTI C ET AL.: "Comparative analysis of circulating tumor DNA stability In KEDTA, Streck, and CellSave blood collection tubes", CLIN BIOCHEM, 2016
   BARTLETT TE; JONES A; GOODE EL; FRIDLEY BL; CUNNINGHAM JM; BERNS EM ET AL.: "Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers", PLOS ONE, vol. 10, no. 12, 2015, pages e0143178
   TESCHENDORFF AE; LEE SH; JONES A; FIEGL H; KALWA M; WAGNER W ET AL.: "HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer", GENOME MED, vol. 7, no. 1, 2015, pages 108, XP021230986, DOI: doi:10.1186/s13073-015-0233-4

DOI:   http://dx.doi.org/10.1186/s13073-015-0233-4
   TESCHENDORFF AE; YANG Z; WONG A; PIPINIKAS CP; JIAO Y; JONES A ET AL.: "Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer", JAMA ONCOL, vol. l, no. 4, July 2015 (2015-07-01), pages 476 - 85
   BARTLETT TE; CHINDERA K; MCDERMOTT J; BREEZE CE; COOKE WR; JONES A ET AL.: "Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution", NAT COMMUN, vol. 7, 2016, pages 11620
   GENTLEMAN RC; CAREY VJ; BATES DM; BOLSTAD B; DETTLING M; DUDOIT S ET AL.: "Bioconductor: open software development for computational biology and bioinformatics", GENOME BIOL, vol. 5, no. 10, 2004, pages R80, XP021012842, DOI: doi:10.1186/gb-2004-5-10-r80

DOI:   http://dx.doi.org/10.1186/gb-2004-5-10-r80
   ARYEE MJ; JAFFE AE; CORRADA-BRAVO H; LADD-ACOSTA C; FEINBERG AP; HANSEN KD ET AL.: "Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays", BIOINFORMATICS, vol. 30, no. 10, 15 May 2014 (2014-05-15), pages 1363 - 9
   TESCHENDORFF AE; MARABITA F; LECHNER M; BARTLETT T; TEGNER J; GOMEZ-CABRERO D ET AL.: "A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data", BIOINFORMATICS, vol. 29, no. 2, 15 January 2013 (2013-01-15), pages 189 - 96
   DEDEURWAERDER S; DEFRANCE M; CALONNE E; DENIS H; SOTIRIOU C; FUKS F: "Evaluation of the Infinium Methylation 450K technology", EPIGENOMICS, vol. 3, no. 6, December 2011 (2011-12-01), pages 771 - 84, XP055259694, DOI: doi:10.2217/epi.11.105

DOI:   http://dx.doi.org/10.2217/epi.11.105
   GOECKS J; NEKRUTENKO A; TAYLOR J: "Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences", GENOME BIOL, vol. 11, no. 8, 2010, pages R86, XP021085640, DOI: doi:10.1186/gb-2010-11-8-r86

DOI:   http://dx.doi.org/10.1186/gb-2010-11-8-r86
   GIARDINE B; RIEMER C; HARDISON RC; BURHANS R; ELNITSKI L; SHAH P ET AL.: "Galaxy: a platform for interactive large-scale genome analysis", GENOME RES, vol. 15, no. 10, October 2005 (2005-10-01), pages 1451 - 5
   GU H; SMITH ZD; BOCK C; BOYLE P; GNIRKE A; MEISSNER A: "Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling", NAT PROTOC, vol. 6, no. 4, April 2011 (2011-04-01), pages 468 - 81, XP055151116, DOI: doi:10.1038/nprot.2010.190

DOI:   http://dx.doi.org/10.1038/nprot.2010.190
   LEE YK; JIN S; DUAN S; LIM YC; NG DP; LIN XM ET AL.: "Improved reduced representation bisulfite sequencing for epigenomic profiling of clinical samples", BIOL PROCED ONLINE, vol. 16, no. 1, 2014, pages 1, XP021172647, DOI: doi:10.1186/1480-9222-16-1

DOI:   http://dx.doi.org/10.1186/1480-9222-16-1
   CHEN PY; COKUS SJ; PELLEGRINI M: "BS Seeker: precise mapping for bisulfite sequencing", BMC BIOINFORMATICS, vol. 11, 2010, pages 203, XP021071546, DOI: doi:10.1186/1471-2105-11-203

DOI:   http://dx.doi.org/10.1186/1471-2105-11-203
   BERNSTEIN DL; KAMESWARAN V; LE LAY JE; SHEAFFER KL; KAESTNER KH: "The BisPCR(2) method for targeted bisulfite sequencing", EPIGENETICS CHROMATIN, vol. 8, no. 27, 2015
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.